Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.

Published in:

2009

By:

• Reardon DA;
• Egorin MJ;
• Desjardins A;
• Vredenburgh JJ;
• Beumer JH;
• Lagattuta TF;
• Gururangan S;
• Herndon JE 2nd;
• Salvado AJ;
• Friedman HS;
• Reardon, David A;
• Egorin, Merrill J;
• Desjardins, Annick;
• Vredenburgh, James J;
• Beumer, Jan H;
• Lagattuta, Theodore F;
• Gururangan, Sridharan;
• Herndon, James E 2nd;
• Salvado, August J;
• Friedman, Henry S

Publication type:

journal article